Drug Profile
Research programme: peptide-based disruptive therapies - SignaBlok
Alternative Names: TREM-1 inhibitors - SignaBlokLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator SignaBlok
- Class Peptides
- Mechanism of Action Signal transduction pathway modulators; TREM modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lung cancer; Sepsis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Lung-cancer in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Sepsis in USA
- 25 Sep 2014 SignaBlok receives SBIR grant from The National Institute of Arthritis and Musculoskeletal and Skin Diseases for development of peptide-based therapy in Rheumatoid arthritis